Giuseppina Lamantia

Giuseppina Lamantia

Auto-generated profile, based on publicly available information

Giuseppina Lamantia

Cardiology Division, European Institute of Oncology, I.R.C.C.S., Milan, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Circulation
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
GBGiulia Bacchiani
Giulia Bacchiani
ITInes Tedeschi
Ines Tedeschi
CMCarlo A. Meroni
Carlo A. Meroni
CCCarlo M. Cipolla
Carlo M. Cipolla
Background—: Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking. We prospectively evaluated incidence, time of occurrence, clinical correlates, and response to heart failure therapy of cardiotoxicity. Methods and Results—: We assessed left ventricular ejection fraction (LVEF), at baseline, every 3 months during chemotherapy and for the following year, every 6 months over the following 4 years, and yearly afterward in a heterogeneous cohort of 2625 patients receiving anthracycline-containing therapy. In case of cardiotoxicity (LVEF decrease >10 absolute points, and 5 absolute points and >50%) or full (LVEF increase to the baseline value). The median follow-up was 5.2 (quartile 1 to quartile 3, 2.6–8.0) years. The overall incidence of cardiotoxicity was 9% (n=226). The median time elapsed between the end of chemotherapy and cardiotoxicity development was 3.5 (quartile 1 to quartile 3, 3–6) months. In 98% of cases (n=221), cardiotoxicity occurred within the first year. Twenty-five (11%) patients had full recovery, and 160 (71%) patients had partial recovery. At multivariable analysis, end-chemotherapy LVEF (hazard ratio, 1.37; 95% confidence interval, 1.33–1.42 for each percent unit decrement) and cumulative doxorubicin dose (hazard ratio, 1.09; 95% confidence interval, 1.04–1.15 for each 50 mg/m 2 increment) were independent correlates of cardiotoxicity. Conclusions—: Most cardiotoxicity after anthracycline-containing therapy occurs within the first year and is associated with anthracycline dose and LVEF at the end of treatment. Early detection and prompt therapy of cardiotoxicity appear crucial for substantial recovery of cardiac function.

1 January 2010 in JACC
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
GLGiuseppina Lamantia
Giuseppina Lamantia
NCNicola Colombo
Nicola Colombo
MCMaurizio Civelli
Maurizio Civelli
CCCarlo M. Cipolla
Carlo M. Cipolla

5 December 2006 in Circulation
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
MSMaria T. Sandri
Maria T. Sandri
GLGiuseppina Lamantia
Giuseppina Lamantia
NCNicola Colombo
Nicola Colombo
CCCarlo M. Cipolla
Carlo M. Cipolla
Background— An increase in troponin I soon after high-dose chemotherapy (HDC) is a strong predictor of poor cardiological outcome in cancer patients. This finding has important clinical implications and provides a rationale for the development of prophylactic strategies for preventing cardiotoxicity. Angiotensin-converting enzyme inhibitors slow the progression of left ventricular dysfunction in different clinical settings, but their role in the prevention of cardiotoxicity has never been investigated. Methods and Results— Of the 473 cancer patients evaluated, 114 (72 women; mean age, 45±12 years) who showed a troponin I increase soon after HDC were randomized to receive (angiotensin-converting enzyme inhibitor group; 20 mg/d; n=56) or not to receive (control subjects; n=58) enalapril. Treatment was started 1 month after HDC and continued for 1 year. Cardiological evaluation was performed at baseline and at 1, 3, 6, and 12 months after HDC. The primary end point was an absolute decrease >10 percent units in left ventricular ejection fraction, with a decline below the normal limit value. A significant reduction in left ventricular ejection fraction and an increase in end-diastolic and end-systolic volumes were observed only in untreated patients. According to the Kaplan-Meier analysis, the incidence of the primary end point was significantly higher in control subjects than in the angiotensin-converting enzyme inhibitor group (43% versus 0%; P <0.001). Conclusions— In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.

8 June 2004 in Circulation
Verified
Journal Article
Open access
PDF file
DCDaniela Cardinale
Daniela Cardinale
MSMaria T. Sandri
Maria T. Sandri
ACAlessandro Colombo
Alessandro Colombo
NCNicola Colombo
Nicola Colombo
MBMarina Boeri
Marina Boeri
CCCarlo M. Cipolla
Carlo M. Cipolla
Background— In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left ventricular dysfunction. The time course of the subclinical myocardial damage and its impact on the clinical outcome have never been investigated previously. Methods and Results— In 703 cancer patients, we measured TnI soon after chemotherapy (early TnI) and 1 month later (late TnI). Troponin was considered positive for values ≥0.08 ng/mL. Clinical and left ventricular ejection fraction evaluation (echocardiography) were performed before chemotherapy, 1, 3, 6, and 12 months after the end of the treatment, and again every 6 months afterward. Three different TnI patterns were identified, and patients were grouped accordingly. In 495 patients, both early and late TnI values were <0.08 ng/mL (TnI −/− group); in 145, there was only an early increase (TnI +/− group); and in 63 patients, both values increased (TnI +/+ group). In the TnI −/− group, no significant reduction in ejection fraction was observed during the follow-up, and there was a very low incidence of cardiac events (1%). In contrast, a greater incidence of cardiac events occurred in TnI-positive patients, particularly in the TnI +/+ group (84% versus 37% in the TnI +/− group; P <0.001). Conclusions— TnI release pattern after high-dose chemotherapy identifies patients at different risks of cardiac events in the 3 years thereafter. This stratification allows us to differentiate the monitoring program and to plan, in selected patients, preventive strategies aimed at improving clinical outcome.

1 September 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
RTRosalba Torrisi
Rosalba Torrisi
MSMaria T. Sandri
Maria T. Sandri
MCMaurizio Civelli
Maurizio Civelli
CCCarlo M. Cipolla
Carlo M. Cipolla
Purpose: Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity in up to 34% of the patients. In most patients, trastuzumab-induced cardiotoxicity (TIC) is reversible: left ventricular ejection fraction (LVEF) improves after trastuzumab withdrawal and with, or sometimes without, initiation of heart failure (HF) therapy. The reversibility of TIC, however, is not foreseeable, and identification of patients at risk and of those who will not recover from cardiac dysfunction is crucial. The usefulness of troponin I (TNI) in the identification of patients at risk for TIC and in the prediction of LVEF recovery has never been investigated. Patients and Methods: In total, 251 women were enrolled. TNI was measured before and after each trastuzumab cycle. LVEF was evaluated at baseline, every 3 months during trastuzumab therapy, and every 6 months afterward. In case of TIC, trastuzumab was discontinued, and HF treatment with enalapril and carvedilol was initiated. TIC was defined as LVEF decrease of > 10 units and below 50%. Recovery from TIC was defined as LVEF increase above 50%. Results: TIC occurred in 42 patients (17%) and was more frequent in patients with TNI elevation (TNI+; 62% v 5%; P < .001). Twenty-five patients (60%) recovered from TIC. LVEF recovery occurred less frequently in TNI+ patients (35% v 100%; P < .001). At multivariate analysis, TNI+ was the only independent predictor of TIC (hazard ratio [HR], 22.9; 95% CI, 11.6 to 45.5; P < .001) and of lack of LVEF recovery (HR, 2.88; 95% CI,1.78 to 4.65; P < .001). Conclusion: TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.

1 August 2000 in JACC
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
MSMaria Teresa Sandri
Maria Teresa Sandri
AMAlessandro Martinoni
Alessandro Martinoni
ALAlessio Tricca LabTech
Alessio Tricca LabTech
MCMaurizio Civelli
Maurizio Civelli
CFCesare Fiorentini
Cesare Fiorentini